News from valeant pharmaceuticals international, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 17, 2014, 09:29 ET
Valeant Pharmaceuticals International, Inc.

Valeant Comments On Allergan Announcement

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc...

Nov 13, 2014, 17:00 ET
Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey

Expansion of its U.S. headquarters solidifies commitment to grow jobs and support the local economy Valeant Pharmaceuticals International,...

Nov 07, 2014, 17:00 ET
Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals Sends Letter To Physician Customers

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today sent a letter to physician customers in order to address...

Nov 04, 2014, 13:27 ET
Valeant Pharmaceuticals International, Inc.

Valeant And Pershing Square May Vote At Special Meeting

 Today, the United States District Court for the Central District of California held that Pershing Square Capital Management, L.P., Valeant...

Oct 27, 2014, 06:55 ET
Valeant Pharmaceuticals International, Inc.

Valeant Delivers Letter To Allergan Board

· Prepared to Improve Offer And Provide Value of at Least $200 a Share · Urges Allergan Board to Take Control of Process...

Oct 20, 2014, 07:00 ET
Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results

  - 2014 Third Quarter Results - Total Revenue $2.1 billion; an increase of 33% over the prior year - Total same store sales...

Oct 15, 2014, 09:17 ET
Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals To Announce 2014 Third Quarter Results On October 20, 2014

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast...

Sep 30, 2014, 11:27 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that the company's Bridgewater, New Jersey location received a...

Sep 26, 2014, 08:00 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Bausch + Lomb Announces Successful Results from Phase 3 Study of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38%

Novel formulation, dosed twice daily, shows superiority to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery in...

Sep 25, 2014, 08:00 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals

 Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced that its Board of Directors has appointed Jeffrey W. Ubben,...

Sep 25, 2014, 02:00 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO® (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies

Expect to file in the U.S. in First Half of Q2 2015 Expect to launch in the U.S. in First Half of 2016 Peak U.S. sales ~$500 million+, Peak...

Sep 24, 2014, 09:05 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director

Overall Same Store Organic Growth (unadjusted for generics) Expected to Exceed 15% in Third Quarter Bausch + Lomb Expected to Continue to Deliver...

Sep 15, 2014, 17:00 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017

 Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX:VRX) today announced that its wholly owned subsidiary, Valeant Pharmaceuticals...

Sep 08, 2014, 17:00 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester

Hosted Ribbon Cutting Ceremony for the New Bausch + Lomb ULTRA® Contact Lens Manufacturing Line and Solar Array Implementation...

Aug 15, 2014, 17:00 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Valeant Extends Offer To Acquire Allergan

 Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced that it has extended the expiration of its exchange offer to...

Aug 11, 2014, 17:30 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) announced that the Company has received a request for additional information from the...

Aug 06, 2014, 15:04 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Institutional Shareholder Services (ISS) Recommends Allergan Shareholders Call A Special Meeting Of Shareholders

Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE:VRX) (TSX: VRX) and Pershing Square Capital Management, L.P. ("Pershing Square")...

Aug 01, 2014, 15:01 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit

 Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management, L.P. today responded to the filing of a...

Jul 31, 2014, 06:00 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results

  - 2014 Second Quarter Total Revenue $2.0 billion; an increase of 86% over the prior year - Overall organic growth was 4% for...

Jul 24, 2014, 08:00 ET
Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.)

Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements

Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE:VRX) (TSX:VRX) announced today that it has filed a detailed complaint with the...